Kolon Eyes H1 Korean Filing For Novel Osteoarthritis Cell Therapy
This article was originally published in Clinica
Executive Summary
Regenerative medicine specialist Kolon Life Science Inc. has unveiled a financing plan to raise production capacity to prepare for the commercialization of Invossa, also known as TissueGene-C, as it aims to file for an approval in South Korea in the first half of this year.